Aprepitant 126(ZZ) combination treatment with Everolimus and

combination treatment with Everolimus and trastuzumab produces the significantly increased inhibition on the growth of cancer stem cells with the inhibition rate increased by more than 50 %

Selective for Bcr-abl over a panel of serine

Formula: C18H19Cl2NO4

It has good activity against a range of HCV genotype variants

4-bis(3-methylthiophen-2-yl)but-3-en-1-yl)piperidine-3-carboxylic acid hydrochloride

Aprepitant 126(ZZ) combination treatment with Everolimus andAprepitant is a small molecule, high affinity substance P antagonist (SPA) with antiemetic activity. Crossing the blood brain barrier, aprepitant binds selectively to the human substance P neurokinin 1 receptor in the central nervous system (CNS), thereby inhibiting receptor binding of endogenous substance P and substance P induced emesis. This agent has little or no affinity for serotonin type 3 (5 HT3), dopamine, and corticosteroid receptors.